Skip to content

Artiva Biotherapeutics, Inc. ARTV Lease Liability Payments - Due Year Two

Lease Liability Payments - Due Year Two at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
$14.04M+3.1%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$163.87K+3.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue-
Operating income-$24.4M-10.2%
Net income-$23.5M-15.8%
EPS (diluted)-$0.95-14.5%

Balance sheet

See full
Cash & equivalents$21.4M-30.6%
Total debt$10.3M-26.7%
Total equity$87.8M-48.0%
Total assets$106.0M-44.6%

Cash flow

See full
Operating cash flow-$21.0M-5.6%
CapEx$242.0K-52.6%
Free cash flow-$21.2M-4.1%

Valuation

See full
Market cap$429.03M+1,015%
Enterprise value$417.88M+1,832%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-67.9%
Debt / equity0.1×0.0×
Current ratio8.2×-5.8×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artiva Biotherapeutics, Inc.'s lease liability payments - due year two.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artiva Biotherapeutics, Inc.'s lease liability payments - due year two?
Artiva Biotherapeutics, Inc. (ARTV) reported lease liability payments - due year two of $3.6M in Q1 2026.
How has Artiva Biotherapeutics, Inc.'s lease liability payments - due year two changed year-over-year?
Artiva Biotherapeutics, Inc.'s lease liability payments - due year two decreased by 1.0% year-over-year, from $3.64M to $3.6M.
What does lease liability payments - due year two mean?
This metric identifies the total cash payments required for operating and finance leases in the second year following the current balance sheet date. It helps investors forecast long-term fixed cost commitments and cash flow requirements. It is essential for modeling the company's future solvency and operational leverage.